title: Severe osteoporosis: diagnosis and follow-up. Lessons for clinical practice.
abstract: The management of osteoporosis has improved considerably, leading to the development of new goals. A major concern today is the management of patients with severe osteoporosis, in whom the need for pharmacotherapy is clear [1]. Epidemiological data have established that osteoporosis is associated with severe complications [2,3]. Furthermore, osteoporosis is now recognized as a complication of several chronic diseases, whose presence adversely affects the management of osteoporosis. The ODISSEE task force (Osteoporosis DIagnosis and Surveillance of SEvErity) was established to answer practical questions regarding the management of severe osteoporosis, based on evidence in the literature. Several groups conducted an exhaustive literature review, and advice was obtained from a panel of French rheumatologists. The ODISSEE scientific committee then developed the first consensus statement on the diagnosis, follow-up and management of severe osteoporosis. This statement was validated by a panel of 70 French rheumatologists at the first national ODISSEE meeting held on November 13-14, 2009.
authors.affiliation: Service de Rhumatologie B, Université Paris-Descartes, Hôpital Cochin, Paris, France. christian.roux@cch.aphp.fr
authors.forename: Christian
authors.initials: C
authors.lastname: Roux
authors.forename: Cyrille B
authors.initials: CB
authors.lastname: Confavreux
authors.forename: Bernard
authors.initials: B
authors.lastname: Cortet
authors.forename: Claire
authors.initials: C
authors.lastname: David
authors.forename: Ariane
authors.initials: A
authors.lastname: Leboime
authors.forename: Michel
authors.initials: M
authors.lastname: Laroche
authors.forename: Erick
authors.initials: E
authors.lastname: Legrand
authors.forename: Christian
authors.initials: C
authors.lastname: Marcelli
authors.forename: Nadia
authors.initials: N
authors.lastname: Mehsen
authors.forename: Julien
authors.initials: J
authors.lastname: Paccou
authors.forename: Thierry
authors.initials: T
authors.lastname: Thomas
mesh_terms: D000367:Age Factors; D000368:Aged; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002446:Celiac Disease / Q000453:epidemiology; D002908:Chronic Disease; D015897:Comorbidity; D032921:Consensus; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology; D007592:Joint Diseases / Q000453:epidemiology; D008297:Male; D009369:Neoplasms / Q000453:epidemiology; D010024:Osteoporosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D058866:Osteoporotic Fractures / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D012307:Risk Factors; D017211:Treatment Failure
chemical_list: D050071:Bone Density Conservation Agents